Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harrigan

Showing results (821-830 of 1,264) with videos related to

Pageof 127
Sort By:
Ethnicity & Disease|December 1, 2005
Oral health disparities and periodontal disease in Asian and Pacific Island populationsRosanne C Harrigan, David Easa, Claude LeSaux, et al.
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1983
Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery systemR H Reuning, S H Liao, A E Staubus, et al.
Journal of Clinical Microbiology|April 19, 2013
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative studyElise Tu, Luke C Swenson, Sally Land, et al.
Current Therapeutic Research, Clinical and Experimental|September 23, 2020
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy VolunteersMarie A Printz, Samuel S Dychter, Emanuel P DeNoia, et al.
Clinical Therapeutics|February 4, 2014
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteersSamuel S Dychter, Rena Harrigan, Jesse D Bahn, et al.
Research Square|July 28, 2023
Application of VirCapSeq-VERT and BacCapSeq In the Diagnosis of Presumed and Definitive Neuroinfectious DiseasesAbhilasha P Boruah, Adam Kroopnick, Riddhi Thakkar, et al.
Journal of Neurovirology|October 18, 2023
Application of VirCapSeq-VERT and BacCapSeq in the diagnosis of presumed and definitive neuroinfectious diseasesAbhilasha P Boruah, Adam Kroopnick, Riddhi Thakkar, et al.
AIDS Care|January 11, 2011
Suboptimal use of HIV drug resistance testing in a universal health-care settingO Eyawo, K A Fernandes, E K Brandson, et al.
The Journal of Infectious Diseases|March 19, 2005
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approachP Richard Harrigan, Brian Wynhoven, Zabrina L Brumme, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2008
The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classesLily W Y Tam, Celia K S Chui, Chanson J Brumme, et al.
Pageof 127

Showing results (821-830 of 1,264) with videos related to

Sort By:
Pageof 127
Ethnicity & Disease|December 1, 2005
Oral health disparities and periodontal disease in Asian and Pacific Island populationsRosanne C Harrigan, David Easa, Claude LeSaux, et al.
Journal of Pharmacokinetics and Biopharmaceutics|August 1, 1983
Pharmacokinetic quantitation of naltrexone controlled release from a copolymer delivery systemR H Reuning, S H Liao, A E Staubus, et al.
Journal of Clinical Microbiology|April 19, 2013
Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative studyElise Tu, Luke C Swenson, Sally Land, et al.
Current Therapeutic Research, Clinical and Experimental|September 23, 2020
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy VolunteersMarie A Printz, Samuel S Dychter, Emanuel P DeNoia, et al.
Clinical Therapeutics|February 4, 2014
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteersSamuel S Dychter, Rena Harrigan, Jesse D Bahn, et al.
Research Square|July 28, 2023
Application of VirCapSeq-VERT and BacCapSeq In the Diagnosis of Presumed and Definitive Neuroinfectious DiseasesAbhilasha P Boruah, Adam Kroopnick, Riddhi Thakkar, et al.
Journal of Neurovirology|October 18, 2023
Application of VirCapSeq-VERT and BacCapSeq in the diagnosis of presumed and definitive neuroinfectious diseasesAbhilasha P Boruah, Adam Kroopnick, Riddhi Thakkar, et al.
AIDS Care|January 11, 2011
Suboptimal use of HIV drug resistance testing in a universal health-care settingO Eyawo, K A Fernandes, E K Brandson, et al.
The Journal of Infectious Diseases|March 19, 2005
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approachP Richard Harrigan, Brian Wynhoven, Zabrina L Brumme, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 11, 2008
The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classesLily W Y Tam, Celia K S Chui, Chanson J Brumme, et al.
Pageof 127